Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 172 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR ‘Dance Moms’ Star Abby Lee Miller Opens Up About Her Cancer... April 19, 2019 Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast September 21, 2021 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Load more HOT NEWS For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining Do Birth Control Pills Impact My Cancer Risk? Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients...
